Ocugen to Showcase Modifier Gene Therapy Platform at Key June Conferences
Event summary
- Ocugen will present its modifier gene therapy platform at three investor and industry conferences in June 2026.
- Presentations include Noble Capital Markets Emerging Growth Virtual Equity Conference on June 4, Clinical Trials at the Summit on June 13, and BIO International Convention on June 23.
- Panel discussion on inherited retinal diseases at Clinical Trials at the Summit includes Ocugen's Shankar Musunuri among other industry experts.
- Webcast of Noble presentation available on Ocugen's investor relations page, with 30-day replay.
The big picture
Ocugen's participation in these high-profile conferences comes as the gene therapy sector continues to evolve, with increasing focus on modifier approaches that can address complex diseases. The company's presentations will be closely watched as investors assess the potential of its platform to treat large patient populations with significant unmet medical needs. The strategic positioning of these conferences suggests Ocugen is aiming to elevate its profile among both investors and industry peers.
What we're watching
- Technology Validation
- How Ocugen's modifier gene therapy platform will be received by investors and industry experts at these key conferences.
- Market Positioning
- Whether Ocugen can differentiate itself in the competitive gene therapy space through these presentations.
- Regulatory Pathway
- The pace at which Ocugen advances its programs for inherited retinal diseases and blindness diseases following these industry engagements.
Related topics